-
Bide Pharmatech Set for IPO on Shanghai’s STAR Market
•
Shanghai-based Bide Pharmatech Co., Ltd, a specialist in drug building blocks, is set to make an initial public offering (IPO) of 16 million shares on the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR), raising an estimated RMB 43.44 million (USD 6.2 million). The move marks a significant milestone for the…
-
Vathin Medical Instrument Raises Pre-Series B Funding Led by IDG Capital
•
China-based single-use bronchoscope specialist Hunan Vathin Medical Instrument Co., Ltd reportedly raised “hundreds of millions” of renminbi in a Pre-Series B financing round led by IDG Capital. Other investors included Founder Securities and Hunan Xiangtan Caixin Chanxing Equity Investment Partnership. The proceeds will be used to ramp up the company’s…
-
Leadinno Medical Valley Raises RMB 100M in Series A Financing for Neuromodulation Devices
•
Beijing-based neuromodulation medical device maker Leadinno Medical Valley reportedly raised over RMB 100 million (USD 14.4 million) in a Series A financing round led by Proxima Ventures and Med-Fine Capital. Other investors included TigerYeah Capital, Maron Investment, and Cowin Capital. The proceeds will be used for research and development (R&D)…
-
Suzhou InnoBM Pharmaceuticals Raises Series A+ Funding for Tumor Immunotherapy
•
China-based Suzhou InnoBM Pharmaceuticals reportedly raised tens of millions of renminbi in a Series A+ financing round led by Yuanbio Venture Capital. The proceeds will be used to advance clinical studies for tumor immunotherapies and develop pipeline candidates based on its unique biomaterial technology platform. Company BackgroundFounded in 2019, InnoBM…
-
Huadong Medicine Pays EUR 105M for 35% Stake in Heidelberg Pharma
•
China’s Huadong Medicine Co., Ltd (SHE: 000963) announced that it has paid a total of EUR 105 million (USD 105 million) to Germany-based Heidelberg Pharma AG (FSE: HPHA) in three installments, as per the agreement signed in February this year. Stake and Board RepresentationAs of the deal’s closure, Huadong holds…
-
CMS’s Rxilient Medical Licenses Insulin Products from Hefei Tianmai Biotech
•
China Medical System Holdings (CMS; HKG: 0867) announced that its subsidiary Rxilient Medical Pte. Ltd has entered into a licensing, collaboration, and supply agreement with Hefei Tianmai Biotechnology Co. Ltd regarding its second-generation insulin and third-generation insulin analogue insulin glargine. Under the agreement, CMS will hold exclusive licensing rights to…
-
Fosun Pharma’s Controlling Shareholder to Sell 3% Stake for USD 461 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) announced that its controlling shareholder, Shanghai Fosun High Technology (Group) Co., Ltd—a subsidiary of Fosun International—is set to sell a holding of 80 million shares, or a 3% stake, in the firm. The sale is expected to bring in RMB 3.22 billion…
-
Junshi Biosciences Plans USD 572M Private Placement to Fund Drug R&D and Expansion
•
China’s Shanghai Junshi Biosciences Co., Ltd (SHA: 688180, HKG: 1877) announced plans to raise up to RMB 3.97 billion (USD 572 million) via private placement, with proceeds allocated to novel drug R&D and construction of its headquarters and R&D facilities. The move underscores the firm’s ambition to accelerate pipeline development…
-
BoomRay Pharmaceuticals Raises USD 43M in Series A for RDC Pipeline Expansion
•
China’s BoomRay Pharmaceuticals, a specialist in radionuclide drug conjugates (RDCs), reportedly raised nearly RMB 300 million (USD 43.2 million) in a Series A financing round led by Sequoia China. The funding will accelerate clinical development, regulatory filings, and global expansion of its pipeline targeting brain, pancreatic, prostate, and other tumors.…
-
Medim Science Raises Funds for Macrophage-Targeting Biologics in Cancer Therapy
•
Hangzhou-based Medim Science, China’s first pharma firm focused on macrophage-targeting biologics, has reportedly raised tens of millions of renminbi in a new financing round led by Ming Bioventures, with Cowin Venture Capital participating. The funds will support R&D, regulatory filings, and clinical trial applications for its pipeline targeting solid tumors.…
-
U Protech Secures Angel Financing for PROTAC and Molecular Glue Drug Pipeline
•
U Protech, a Hangzhou-based biotech focused on next-generation protein degradation therapies, has raised tens of millions of renminbi in Angel and Angel+ financing rounds. The funding, led by Shanghai Biomedical Industry Equity Investment Fund’s transformation fund and Zheshang Venture Capital, will accelerate development of its PROTAC and molecular glue drug…
-
Neukio Biotherapeutics Completes USD 50M Series A-1 Financing for iPSC-CAR-NK Therapy
•
Shanghai-based Neukio Biotherapeutics, a developer of iPSC-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies, announced the completion of a USD 50 million Series A-1 financing round. The funding, led by CD Capital, will support pre-clinical validation, clinical trials, and talent recruitment for its universal off-the-shelf CAR-NK pipeline. Financing DetailsThe…
-
Acorda Therapeutics Licenses Preclinical Drug Nepicastat to China’s Asieris
•
US-based Acorda Therapeutics Inc. (Nasdaq: ACOR) announced a licensing agreement with China’s Asieris Pharmaceuticals for its preclinical drug candidate nepicastat, a small-molecule inhibitor of dopamine beta-hydroxylase (DBH). Asieris will develop the drug for non-psychiatric indications, with a focus on cardiovascular diseases linked to sympathetic nervous system overactivation. Deal TermsUnder the…
-
Biointron Raises USD 72M in Series B to Expand CRO Services and Antibody Platform
•
Shanghai-based Biointron, a recombinant protein/antibody reagent contract research organization (CRO), has raised nearly RMB 500 million (USD 72.4 million) in a Series B round led by Cornerstone Capital, LYFE Capital, and Sky World Capital. The funding will enhance its CRO service capacity, smart manufacturing, R&D, and global expansion. Funding DetailsThe…
-
E-nitiate Biopharma Raises RMB 100M in Series A to Advance Autoimmune Disease Drugs
•
China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a drug developer focused on autoimmune diseases, has raised RMB 100 million (USD 14.5 million) in a Series A financing round. The round was led by M Momentum Venture and included contributions from Tailong Capital, Hangzhou Linping State-owned Capital Investment, and Hangzhou Jintou Industry…
-
Onekdrug Raises Series B+ Funding to Boost Pharmaceutical B2B Services
•
Hunan Wholesale Pharmaceutical Technology Co., Ltd, operating as Onekdrug, has raised tens of millions of US dollars in a Series B+ financing round led by C-Bridge Capital, with contributions from existing investors Cenova Capital and Unicorn Capital Partners. The proceeds will enhance the company’s service capabilities, including operations, technology, and…
-
Luca Healthcare Raises Pre-Series A Funding for Digital Biomarker R&D
•
Shanghai-based Luca Healthcare Co., Ltd, a firm specializing in digital biomarkers and therapeutics, has raised tens of millions of renminbi in a pre-Series A financing round led by Lightspeed China, with participation from JinDing Capital and Picus Capital. The funds will support R&D, validation of digital target pipelines, international collaborations,…
-
Acchrom Tech Raises USD 14.45M in Angel Round Led by BioTrack Capital to Expand Chromatography Solutions
•
Beijing-based chromatography specialist Acchrom Tech has raised RMB 100 million (USD 14.45 million) in an angel financing round led by BioTrack Capital, with contributions from CDBI Partners and SDIC Unity Capital. The funds will be used to enhance complete chromatography solutions and expand sales channels. Company ProfileFounded in 2015, Acchrom…
-
Shanghai Bao Pharma Raises USD 100M in Series B to Advance Drug Delivery Tech
•
Shanghai Bao Pharmaceuticals Co., Ltd has raised over USD 100 million in a Series B financing round led by Oriental Fortune Capital, with contributions from Haitong Innovation Private Fund, Sun Rock Capital, Center Lab, and YuanChuang Capital. The proceeds will fund commercialization of core drug candidates and pivotal clinical studies…
-
Lab Direct Raises USD 10M in Series A+ to Expand Digital Supply Chain Platform
•
Shanghai-based life science digital supply chain platform Lab Direct has raised USD 10 million in a Series A+ financing round led by Bayland Capital, a joint biomedical fund established by Contract Research Organization (CRO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) and Legend Capital. The round included participation from…
